Skip to main content
TipRanks
Go Ultimate75% OFF

Mochida Pharmaceutical Reports Initial Progress on Share Buyback Program

Mochida Pharmaceutical Reports Initial Progress on Share Buyback Program
Image source: Shutterstock

Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an update.

Mochida Pharmaceutical has disclosed the latest progress of its ongoing share repurchase program authorized under Japan’s Companies Act, confirming it bought back 35,300 common shares on the Tokyo Stock Exchange between May 18 and May 31, 2026, at a total cost of ¥124.3 million via market purchases under a discretionary dealing contract. This initial tranche represents only a small portion of the board-approved ceiling of up to 530,000 shares or ¥2.0 billion to be acquired by December 18, 2026, signaling continued capacity for additional buybacks that could support shareholder returns and potentially enhance capital efficiency over the remainder of the program.

More about Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market under securities code 4534. The company operates in the pharmaceutical industry, focusing on the development, manufacture and sale of prescription medicines and related healthcare products in the domestic Japanese market and potentially abroad.

YTD Price Performance: -1.33%

Average Trading Volume: 116,815

Technical Sentiment Signal: Buy

Current Market Cap: Yen117.4B

See more data about 4534 stock on TipRanks’ Stock Analysis page.

This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.

Disclaimer & DisclosureReport an Issue

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!